Matthew Scaramozza
Biogen (United States)(US)
Publications by Year
Research Areas
Multiple Sclerosis Research Studies, Chronic Lymphocytic Leukemia Research, Rheumatoid Arthritis Research and Therapies, Psoriasis: Treatment and Pathogenesis, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Most-Cited Works
- → Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial(2014)241 cited
- → The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis(2017)91 cited
- → Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis(2020)53 cited
- → Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis(2022)51 cited
- → Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions(2020)41 cited
- → Chronic lesion activity and disability progression in secondary progressive multiple sclerosis(2022)39 cited
- → Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study(2020)32 cited
- → Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis(2012)29 cited
- → Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study(2020)27 cited
- → Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells(2021)24 cited